Total pharma industry deals for June 2019 worth $102.8bn were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 862.05% over the previous month and a rise of 469.4% when compared with the last 12-month average of $18.05bn.
In terms of number of deals, the sector saw a drop of 20% over the last 12-month average with 108 deals against the average of 135 deals.
In value terms, Europe led the activity with deals worth $86.95bn.
Pharma industry deals in June 2019: Top deals
The top five pharma deals accounted for 97.1% of the overall value during June 2019.
The combined value of the top five pharma deals stood at $99.82bn, against the overall value of $102.8bn recorded for the month. The top announced pharma deal tracked by GlobalData in June 2019 was AbbVie’s $85.74bn acquisition of Allergan.
In second place was the $11.4bn acquisition of Array BioPharma by Pfizer and in third place was Vertex Pharmaceuticals‘ $1bn acquisition of Exonics Therapeutics.
The $911.98m acquisition of Global Cord Blood by Cordlife Group and Merck &Inc’s acquisition of Tilos Therapeutics for $773m held fourth and fifth positions, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.